180 related articles for article (PubMed ID: 38161104)
1. A systematic review of nanocarriers for treatment of urologic cancers.
Wang AJY; Yan C; Reike MJ; Black PC; Contreras-Sanz A
Urol Oncol; 2024 Apr; 42(4):75-101. PubMed ID: 38161104
[TBL] [Abstract][Full Text] [Related]
2. Nanomedicine for urologic cancers: diagnosis and management.
Li C; Zeng X; Qiu S; Gu Y; Zhang Y
Semin Cancer Biol; 2022 Nov; 86(Pt 2):463-475. PubMed ID: 35660001
[TBL] [Abstract][Full Text] [Related]
3. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
4. Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature.
Özdemir BC; Siefker-Radtke AO; Campbell MT; Subudhi SK
Eur Urol Focus; 2018 Apr; 4(3):442-454. PubMed ID: 29056275
[TBL] [Abstract][Full Text] [Related]
5. [The possibility of S-1 for the treatment of patients with urological cancers].
Akaza H
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():236-8. PubMed ID: 16898009
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Metformin Use with Survival Outcomes in Urologic Cancers: A Systematic Review and Meta-Analysis.
Yao X; Liu H; Xu H
Biomed Res Int; 2021; 2021():5311828. PubMed ID: 34660791
[TBL] [Abstract][Full Text] [Related]
7. Robotic-assisted minimally invasive surgery for gynecologic and urologic oncology: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(27):1-118. PubMed ID: 23074405
[TBL] [Abstract][Full Text] [Related]
8. Drug insight: Use of docetaxel in prostate and urothelial cancers.
Mackler NJ; Pienta KJ
Nat Clin Pract Urol; 2005 Feb; 2(2):92-100; quiz 1 p following 112. PubMed ID: 16474654
[TBL] [Abstract][Full Text] [Related]
9. [Chemotherapy in urologic oncology].
Deville JL
Prog Urol; 2011 Nov; 21(11):816-21. PubMed ID: 22032608
[TBL] [Abstract][Full Text] [Related]
10. Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis.
Wu Z; Chen Q; Qu L; Li M; Wang L; Mir MC; Carbonara U; Pandolfo SD; Black PC; Paul AK; Di Lorenzo G; Porpiglia F; Mari A; Necchi A; Rouprêt M; Psutka SP; Autorino R
Eur Urol; 2022 Apr; 81(4):414-425. PubMed ID: 35101302
[TBL] [Abstract][Full Text] [Related]
11. Systematic Review of Immune Checkpoint Inhibition in Urological Cancers.
Rijnders M; de Wit R; Boormans JL; Lolkema MPJ; van der Veldt AAM
Eur Urol; 2017 Sep; 72(3):411-423. PubMed ID: 28645491
[TBL] [Abstract][Full Text] [Related]
12. Molecular therapy in urologic oncology.
Froehner M; Hakenberg OW; Wirth MP
Urol Int; 2007; 79(1):1-7. PubMed ID: 17627159
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for the Treatment of Urothelial Carcinoma.
Donin NM; Lenis AT; Holden S; Drakaki A; Pantuck A; Belldegrun A; Chamie K
J Urol; 2017 Jan; 197(1):14-22. PubMed ID: 27460757
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma.
Alva A; Daignault S; Smith DC; Hussain M
Invest New Drugs; 2014 Feb; 32(1):188-94. PubMed ID: 24318901
[TBL] [Abstract][Full Text] [Related]
15. Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers.
Paner GP; Stadler WM; Hansel DE; Montironi R; Lin DW; Amin MB
Eur Urol; 2018 Apr; 73(4):560-569. PubMed ID: 29325693
[TBL] [Abstract][Full Text] [Related]
16. Mortality Trends from Urologic Cancers in Europe over the Period 1980-2017 and a Projection to 2025.
Bertuccio P; Santucci C; Carioli G; Malvezzi M; La Vecchia C; Negri E
Eur Urol Oncol; 2021 Oct; 4(5):677-696. PubMed ID: 34103280
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness research in urologic cancers.
Strope SA
Cancer Treat Res; 2015; 164():221-35. PubMed ID: 25677026
[TBL] [Abstract][Full Text] [Related]
18. Association of metabolic syndrome and its components with the risk of urologic cancers: a prospective cohort study.
Jiang R; Wang X; Li Z; Cai H; Sun Z; Wu S; Chen S; Hu H
BMC Urol; 2023 Sep; 23(1):150. PubMed ID: 37736725
[TBL] [Abstract][Full Text] [Related]
19. [Urological cancer].
Miyanaga N; Akaza H
Gan To Kagaku Ryoho; 2009 Feb; 36(2):193-8. PubMed ID: 19223735
[TBL] [Abstract][Full Text] [Related]
20. Novel therapies for advanced urologic cancers.
Heidenreich A
Curr Opin Urol; 2020 Jul; 30(4):594-601. PubMed ID: 32453002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
